Human immunodeficiency virus infection is still one of the most important causes of morbidity and mortality in the world, with a disproportionate human and economic burden especially in poorer countries. Despite many years of intense research, an aspect that still is not well understood is what (immune) mechanisms control the viral load during the prolonged asymptomatic stage of infection. Because CD8+ T cells have been implicated in this control by multiple lines of evidence, there has been a focus on understanding the potential mechanisms of action of this immune effector population. One type of experiment used to this end has been depleting these cells with monoclonal antibodies in the simian immunodeficiency virus-macaque model and then studying the effect of that depletion on the viral dynamics. Here we review what these experiments have told us. We emphasize modeling studies to interpret the changes in viral load observed in these experiments, including discussion of alternative models, assumptions and interpretations, as well as potential future experiments.
| HIV INFEC TI ON
Human immunodeficiency virus (HIV) is still one of the biggest worldwide causes of morbidity and mortality due to an infectious disease. HIV infects cells of the immune system, particularly CD4+ T cells and macrophages. If untreated, HIV eventually leads to immunodeficiency. As the number of CD4+ T cells decreases during the asymptomatic phase of infection, the HIV-infected individual has more difficulty fighting a suite of opportunistic diseases, which in the end are the cause of death.
During the initial stage of infection (called acute, primary infection), the viral levels increase exponentially over the first few weeks, reach a peak after 2-4 weeks from the time of infection and then decay until the viral load more or less stabilizes at the chronic phase set-point level, starting from approximately 4-6 weeks postinfection. 1 The chronic phase of viral infection is a protracted period with variable duration, during which the patient is asymptomatic and the viral load is relatively stable. 2 However, the number of CD4+ T cells declines continuously over this period and when the number of these cells falls below 200 cells/μL, the patient enters the stage of AIDS (acquired immunodeficiency syndrome). This stage is traditionally characterized by the opportunistic diseases that eventually lead to the patient death. With the advent of antiretroviral therapy (ART), this classic pattern of disease progression, opportunistic infection and cancers was replaced with a more proteiform clinical presentation, characterized by multiple comorbidities triggered by persistent inflammation, such as hypercoagulability, cardiovascular disease, osteoporosis, nonalcoholic fatty liver disease, renal disease, or accelerated aging. [3] [4] [5] One of the most puzzling aspects of HIV infection is that it is one of the few (perhaps the only) infections for which there is 
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This article is part of a series of reviews covering Modeling Viral Infection and Immunity appearing in Volume 285 of Immunological Reviews. no reliable record of an infected person recovering without medical help. And indeed, with the exception of a very special case, 6 no one has ever been able to eradicate the virus once infected, even in the setting of very powerful ART. This observation is even more difficult to understand because HIV elicits vigorous immune responses, including innate, humoral, and cellular effector mechanisms. 7 For example, it has been clearly described that cellular immune responses, as measured by antigen-specific CD8+ T cell expansion, are similar or greater in HIV compared to other chronic diseases. 8, 9 Fortunately, ART is very efficient in reducing viral loads to undetectable levels (e.g., <50 copies/mL) in the vast majority of treated infected individuals. However, ART is not available to everyone infected. Furthermore, ART is virostatic, that is, it reduces viral load, but does not lead to viral eradication. Thus, an important goal of HIV research is the development of a safe and effective vaccine to prevent infection in the first place. To this end, it is crucial to have a better understanding of immunity against the virus. Among these, the most studied, and (perhaps consequently) the one for which there is the most evidence for an effect in controlling HIV, is the cellular immune response mediated by CD8+ T cells.
| HIV IMMUNE CONTROL
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Several lines of evidence indicate that CD8+ T cells are an important factor in controlling HIV infection. This evidence includes the temporal association between HIV-1 decline after peak viremia in acute infection and the appearance of a CD8+ T-cellspecific response, 12 the association between an infected person's human leukocyte antigen (HLA) genotype and the course of infection (pathogenesis) and viral load set-point 13, 14 ; the mutation of virus at key residues (epitopes) to escape the immune response pressure of CD8+ T cells, 15, 16 leading to an effective adaptation of the virus to persist in the infected host. This is confirmed at the population level as an evolution of the virus to adapt to prevalent HLA genotypes. 17 Meanwhile, experiments designed to change the numbers of CD8+ T cells in circulation have an important (but variable) impact on viral load. These include experiments to increase the number of CD8+ T cells, such as infusion of these cells [18] [19] [20] [21] [22] [23] [24] and studies of vaccines leading to large expansions of the circulating CD8+ T-cell counts. 25, 26 The opposite approach, trying to reduce CD8+ cells, by infusion of depleting antibodies, has also been attempted in simian immunodeficiency virus (SIV)
animal models, usually leading to significant increases in viral load. 27, 28 Alternative interpretations of these various results point to a more limited impact of CD8+ T-cell responses in viral control. Thus, for example, the viral decay from the peak is indeed concomitant with the appearance of HIV-specific CD8+ T cells, but could also be explained by the reduction in target cell availability as a result of virus cytopathic effects. 29 Furthermore, while it is expected that the control of viral load during treatment should depend on the quality of the CD8+ T-cell response, a study specifically analyzing the effect of HLA on the viral dynamics observed in patients put on antiretroviral treatment found no difference between protective alleles and other HLA types. 30 The same is true of treatments early and late in infection, when it would be expected that the CD8+ T-cell response should be weaker, but no differences in viral dynamics were found. 29, 31 Thus, although multiple studies suggest a role for CD8+ T cells, the specific mechanisms by which these cells act in vivo are not un- Figure 1B ).
These studies were taken as strong, if not the main, evidence for an important effect of CD8+ cells in controlling the virus-and likely were one of the key aspects for the rational to develop CD8+ Tcell-based vaccines. 26 Subsequent studies used this experimental approach to try to characterize in more detail the biology of HIV/ SIV infection and the mechanisms of action of the CD8+ cells. [41] [42] [43] [44] [45] [46] [47] For example, the contrasting results of depleting these cells in pathogenic models of SIV versus natural hosts of SIV, which do not develop overt disease, were analyzed in multiple studies. [48] [49] [50] [51] One of the most common uses of CD8+ cell depletion is to investigate the effects of vaccine protocols. In these studies, a SIV vaccination and challenge protocol is implemented and when control of virus below the levels of placebo is found, often CD8+ cell depletion is performed to ascertain if these cells are important in the observed control. [52] [53] [54] [55] [56] [57] [58] [59] Another common use is in a model of SIV-induced en-
cephalitis (SIVE). Depletion of CD8+ cells in primary infection leads
to high viral loads and rapid progression, including a high incidence of SIVE, more than double in comparison to infection in nondepleted animals.
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Here we focus on studies of CD8+ cell depletion during chronic infection, because some of these experiments have been analyzed in more detail through modeling. As schematically shown in Figure 1B , administration of a CD8-depleting antibody during chronic infection leads to a profound depletion of CD8+ cells in the periphery, although depletion at other sites, such as lymph node and mucosa, is usually less pronounced and more variable. 63 At the same time, the viral load increases quickly.
| CD8-depletion experiments during chronic SIV infection
For a better understanding of the viral dynamics after CD8+ cell depletion, we reviewed in detail the data from 14 studies of experiments in macaques chronically infected with SIV and depleted of CD8+ cells. We included all studies that we could find with CD8+ cell depletion in SIV chronic infection, which had data on the viral dynamics in individual animals. Altogether, we collected data from 78 individual macaques. In Table 1 , we summarize the main characteristics of these studies. (Note that Gadhamsetty et al 64 also presented a summary of some of these studies.)
The studies included in this analysis had multiple objectives. Jin et al and Schmitz et al 27, 28 were two of the first studies to be pub- 
| Dynamics of viral load post CD8+ cell depletion
In the studies analyzed, CD8+ cell depletion resulted in viral load increases that reached a peak on average 8.2 days later (range 2 to ~22 days) and this peak was on average ~225-fold above the pre- That is, those macaques with the highest change in viral load, also increase the fastest ( Figure 3B ).
One interpretation of these observations is that a better control imposed by CD8+ cells, in those macaques with lower viral loads predepletion, is revealed by the largest increases postdepletion.
However, another possibility is that lower viral loads in those macaques also results in better preservation of CD4+ T cells, and thus more targets for infection when immune control is relaxed.
| MATHEMATI C AL MODELING OF CD8+ CELL DEPLE TI ON E XPERIMENTS
The dynamic changes in viral load observed when CD8+ cells are crease. Finally, they also considered that CD8+ cells produce antiviral factors that block viral production, and absence of these cells would lead to higher levels of viral production, p. Interestingly, although all these putative mechanisms resulted in viral increase, none of them by itself provided dynamic profiles similar to those observed. Still, the most similar profile was obtained by an increase in p. This result was somewhat surprising, because it was expected that CD8+ T cells had a strong cytotoxic activity, and in that case killing of infected cells should be a major mechanism of viral control.
(1)
Correlation of viral load predepletion with (A) peak viral load postdepletion and (B) fold-increase during depletion. The strength and significance of the Spearman rank correlation are shown. See Table 1 for the description of the studies and corresponding references. The data presented were digitized for most of the studies, with the exception of our own and, 41 for which we have the original data
F I G U R E 3 Correlation of viral load up-slopes during depletion with (A) viral load predepletion and (B) fold-increase during depletion.
The strength and significance of the Spearman rank correlation are shown. See Table 1 32, 33 In Figure 4A , we represent schematically the design of these studies. The hypothesis of these studies as stated in Klatt et al 32 was "that CD8+ T-cell-mediated CTL activity will result in reduced production of virions per infected cell due to a significant shortening of the average in vivo lifespan of productively SIV-infected cells." Both studies used a model similar to the one presented in Equation (1) The authors of those studies confirmed an important effect of CD8+ cells, but refuted an effect on the life-span of productively infected cells. This led to a flurry of alternative hypothesis for the mechanism of action of CD8+ T cells, already in those two studies, but also in many subsequent papers. Two of the most interesting hypotheses were that either the effect of CD8+ cells was (a) through noncytolytic effects that did not reduce the lifespan of infected cells 32, 33 ; or (b) that more detailed models of the viral lifecycle, for example, including an eclipse phase before viral production 32, 33, 72 or an exponential increase in viral production, 73 could be compatible with the data and with an important cytolytic effect.
In support of the first explanation, there are many experimental observations that are consistent with a noncytolytic effect of CD8+ T cells. In this context, multiple soluble factors have been found or proposed to reduce viral replication (reviewed in 11).
Indeed, the possibility of a nonlytic effect was also the conclusion of one of the first studies of chronically SIV-infected macaques depleted of CD8+ cells described above, 27 where it was found that an effect in viral production was more consistent with the data. Moreover, a re-analysis of the experimental data by Klatt et al comparing models with cytolytic and noncytolytic effects concluded that the latter had more support. 74 Modeling data on rates of escape from CD8+ T cells in SIV infection also indicated that the observations were more consistent with noncytolytic effects. 75 One issue with the hypothesis of noncytolytic effects is that if these are mediated by soluble factors, then they may not be strain/epitope specific and thus would not be able to drive viral escape from CD8 responses. However, another modeling study showed that there are conditions when noncytolytic responses can also drive-specific mutations escaping CD8-mediated control.
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A different explanation for the similarity of decay rates of virus in monkeys depleted of CD8+ cells or not, and treated with ART is that the lifecycle of SIV is more complex than the way it was modeled in corresponds to events between cell entry and viral production. 78, 79 Moreover, experimental observations show that viral epitopes are expressed on the surface of the infected cell very early on 80, 81 and that later there is viral-induced MHC downregulation from the surface of infected cells, through the action of the HIV nef protein, [82] [83] [84] making CTL targeting less efficient. 85 These two facts support the notion that immune-mediated killing of infected cells could occur early, before the cells start producing virus, and thus that CD8+ T cells could have important cytolytic activity. would always reflect the rate of the slowest phase. This was studied in great detail and elegance in a recent paper by Gadhamsetty et al, 64 where they concluded that although not proving that CD8+ cells had a cytolytic mechanism of action, "we have shown that all experiments that were previously taken to favor nonlytic control by CD8+ T cells are perfectly consistent with a pure cytotoxic mechanism of control."
Another proposal to reconcile a cytolytic mechanism with the observation of no decrease in productively infected cell lifespan was based on the idea that viral production is likely not constant, but increases over time since infection. 73 In this model, viral production by infected cells increases exponentially after an eclipse phase and cytolytic activity is present throughout, but also increasing with time since infection. The authors showed that such a model could reproduce the previous experimental results, because it only predicted small differences in the slopes of decay of viral load in depleted vs.
nondepleted animals. 73 In this scenario, immune-mediated killing would occur just before the cells would die from viral cytopathic effects 86 and thus would not shorten the lifespan by much. These differences would be too small to be detectable in the experiments due to the variability in slopes from animal to animal and the relatively small numbers of macaques studied. Interestingly a prior study already addressed the issue of statistical power to detect differences in infected cell lifespan in the (necessary small-sample) animal studies. 74 The authors concluded that it was possible that a lytic effect would be small and not observable in the experiments. 74 In conclusion, the relatively simple and straightforward inter- 
| TRE ATMENT WITH INTEG R A S E INHIB ITOR S AND CD8+ CELL DEPLE TI ON
| Dynamics of viral load under integrase inhibitor therapy
The CD8+ cell depletion and treatment experiments discussed 32, 33 used the same ART protocol based on a combination of reverse transcriptase inhibitors (RTI). These drugs block viral replication early in the viral lifecycle and lead to a single exponential decay of viral load early after treatment is started, which corresponds, as mentioned above, to the slower of any subsequent stages of the lifecycle. 64, [86] [87] [88] In addition, to interpret CD8+ cell depletion experiments, it is often assumed that cytolytic activity occurs at some stage after the step blocked by treatment, 64 in this case reverse transcription.
Studies modeling the viral load decline in chronically infected patients treated with regimens containing the integrase strand transfer inhibitor (InSTI) raltegravir (RAL), which affects a stage of the virus life cycle after reverse transcription, show a pattern of virus decline very distinct from previous studies with RTIs. [13] [14] [15] [16] Two recent modeling studies analyzed the viral load decline in two sets of infected patients receiving RAL, in one case treatment was monotherapy for a period of 9 days, 15 and in the other infected individuals received
RTIs and RAL, with frequent sampling of the viral load over the first 28 days of treatment. 14 In both studies, plasma viral load decline during the first 10 days of therapy presented an early fast phase of decay (phase 1a) followed by a slower phase of decay (phase 1b). ω) ). 89, 90 This model is similar to the one proposed by Gadhamsetty et al, 64 but treatment with the integrase inhibitor occurs at a later stage of infection than with RTIs, and crucially treatment reverses what is the slow and the fast phases of the lifecycle.
| Predictions of viral decline under RAL therapy and CD8+ cell depletion
In the context of model (3) Whether these results are in agreement with the schematic results predicted by the modeling and depicted in Figure 7 is still under investigation.
| CON CLUS IONS
HIV infection is still one of the largest causes of morbidity and mortality across the globe. More than 35 years after it first appeared on the world stage, our knowledge of its pathogenesis, 
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